Drugdocs | Zulresso

An independent source of information on U.S. brand name drugs for health professionals

An independent source of information on U.S. brand name drugs for health professionals

Zulresso

Chemical Name	brexanolone
Dosage Form	Injectable (intravenous; 5 mg/mL)
Drug Class	Modulators
System	Nervous
Company	Sage Therapeutics
Approval Year	2019

Indication

Zulresso is indicated for the treatment of postpartum depression (PPD) in adults.

Last updated on 10/28/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document Title	Year	Source
Zulresso (brexanolone) Prescribing Information	2019	Sage Therapeutics

Document Title	Year	Source
Brexanolone for postpartum depression: A meta-analysis of randomized controlled studies.	2019	Psychiatry Research